首页> 外文期刊>Contraception >Effectiveness, safety and acceptability of Sino-implant (II) during the first year of use: Results from Kenya and Pakistan
【24h】

Effectiveness, safety and acceptability of Sino-implant (II) during the first year of use: Results from Kenya and Pakistan

机译:使用第一年中草药植入物(II)的有效性,安全性和可接受性:肯尼亚和巴基斯坦的结果

获取原文
获取原文并翻译 | 示例
       

摘要

Background Sino-implant (II) is a two-rod subcutaneous contraceptive implant used up to 4 years, containing 150 mg of levonorgestrel. We conducted two observational studies of Sino-implant (II) to evaluate its performance in routine service delivery settings. Methods We enrolled 1326 women age 18-44 who had Sino-implant (II) inserted at clinics in Pakistan and Kenya. Women were followed-up using either an active or passive follow-up scheme in each study. Study outcomes were: one-year cumulative pregnancy and discontinuation rates; rates of insertion and removal complications; adverse event and side effect rates; reasons for discontinuation; and implant acceptability and satisfaction with clinic services. Results A total of 754 women returned for at least one follow-up visit. The overall Pearl pregnancy rate was 0.4 per 100 woman-years [95% confidence interval (CI) 0.1, 0.9] resulting from 1 confirmed post-insertion pregnancy in Kenya and 4 in Pakistan. Country-specific Pearl rates were 0.2 (95% CI 0.0, 0.9) in Kenya and 0.6 (95% CI 0.2, 1.6) in Pakistan. The total cumulative 12-month probability of removal was 7.6% (95% CI 6.1, 9.1), with country-specific removal probabilities of 3.7% in Kenya (95% CI 2.1, 5.3) and 10.8% in Pakistan (95% CI 8.5, 13.2). Four serious adverse events occurred in Kenya and none occurred in Pakistan; one SAE (an ectopic pregnancy) was possibly related to Sino-implant (II). Most women in both countries said they would recommend the implant to others. Conclusion The results from these studies reveal high effectiveness and favorable safety and acceptability during the first year of use of Sino-implant. Implication The favorable Sino-implant (II) findings from Kenya and Pakistan provide further evidence from disparate regions that Sino-implant (II) is safe, effective and acceptable during routine service delivery.
机译:背景技术中药植入物(II)是一种两杆式皮下避孕植入物,使用期长达4年,含有150 mg左炔诺孕酮。我们对中植入物(II)进行了两项观察性研究,以评估其在常规服务提供环境中的性能。方法我们招募了1326名年龄在18-44岁的女性,他们在巴基斯坦和肯尼亚的诊所中插入了中植入物(II)。在每项研究中,均采用主动或被动的随访方案对妇女进行了随访。研究结果为:一年累积妊娠和终止妊娠率;插入和取出并发症的发生率;不良事件和副作用发生率;停产原因;以及对临床服务的接受度和满意度。结果共有754名妇女至少返回了一次随访。总体而言,珍珠怀孕率为每100个妇女年0.4个[95%置信区间(CI)0.1、0.9],这是由肯尼亚1例确诊的插入后妊娠和巴基斯坦4例确诊的。肯尼亚的特定国家/地区珍珠率是0.2(95%CI 0.0,0.9),巴基斯坦是0.6(95%CI 0.2,1.6)。过去12个月的累计去除总概率为7.6%(95%CI 6.1,9.1),肯尼亚特定国家/地区的去除率分别为3.7%(95%CI 2.1,5.3)和巴基斯坦的10.8%(95%CI 8.5) ,13.2)。肯尼亚发生了四次严重的不良事件,巴基斯坦未发生;一种SAE(异位妊娠)可能与中植入物有关(II)。两国的大多数妇女表示,他们将向其他人推荐植入物。结论这些研究的结果表明,在使用中国植入物的第一年中,其有效性高,安全性和可接受性良好。启示肯尼亚和巴基斯坦对中植入物(II)的满意研究结果为不同地区提供了进一步的证据,表明中植入物(II)在常规服务提供过程中是安全,有效且可以接受的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号